Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohnʼs Disease

Walters, Thomas D.; Faubion, William A.; Griffiths, Anne M.; Baldassano, Robert N.; Escher, Johanna C.; Ruemmele, Frank M; Hyams, Jeffrey S.; Lazar, Andreas; Eichner, Samantha; Huang, Bidan; Li, Yao; Thakkar, Roopal

doi:10.1097/mib.0000000000001075

Cited by 25 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 In the CD study, adalimumab sig-nificantly normalized the growth rate by week 26 (median height velocity z score, −0.34) and week 52 (0.21; both P < .001) in patients with baseline growth impairment (n = 73). 18 Linear growth remained stable over time in patients without baseline growth impairment (n = 27).…”

Section: Growthmentioning

confidence: 97%

See 1 more Smart Citation

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease

Horneff

Seyger

Arikan

et al. 2018

The Journal of Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Growthmentioning

confidence: 97%

“…Patients with height velocity z score ≤-1.0 were considered to have growth delay at baseline. 18 Change from baseline in height velocity z score was evaluated in patients with and without growth delay at baseline.…”

Section: Safety Assessmentsmentioning

confidence: 99%

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease

Horneff

Seyger

Arikan

et al. 2018

The Journal of Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

“…A study from Canada suggested that a positive effect on height velocity was observed only in pre-pubertal or pubertal patients, but was absent in patients with Tanner stage IV-V (43). The IMAgINE 1 study group has suggested that adalimumab also improved and normalized the growth rate of patients with CD at 26 and 52 weeks of treatment compared to baseline (44).…”

Section: Effect Of Ibd Treatment On Growth Of Patients With Pediatricmentioning

confidence: 99%

Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management

Ishige

2019

Transl Pediatr

View full text Add to dashboard Cite

Impairment of growth is recognized as one of the most significant complications of inflammatory bowel disease (IBD) in pediatric patients. The reported incidence of growth failure at diagnosis is 15-40% in pediatric onset Crohn's disease (CD) and 3-10% in ulcerative colitis (UC). Growth failure is associated with decreased appetite, abdominal symptoms, malabsorption due to mucosal inflammation, growth hormone (GH) resistance due to inflammation, and even genetic factors. Several population-based studies and cohort studies suggest that patients with pre-pubertal onset CD have a higher risk of growth failure at disease onset. Final adult height is still lower than that of healthy controls; however, its prevalence is generally lower than that at the disease onset. Several IBD treatments were reported to improve patients' growth. In addition to enteral nutrition therapy, treatment with anti-tumor necrosis factor (TNF) agents was reported to have favorable effects on growth of patients with pre-pubertal onset CD. Avoiding corticosteroids (CS) and achieving deep remission seems to be important to maintain optimal growth in patients with pediatric onset IBD.

show abstract

“…Population-based studies have shown that catch-up growth in pediatric IBD children occurs after initiation of anti-TNFα treatment (Crombé et al 2011;Church et al 2014). In a clinical trial of adalimumab in children with CD, this therapy significantly improved and normalized growth rate at weeks 26 and 52 in patients with baseline growth impairment (Walters et al 2017). Therefore, early anti-TNFα treatment is an example of a personalized treatment intervention for children with CD and linear growth failure.…”

Section: Bone Healthmentioning

confidence: 99%

Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm

Batra

Conklin

2019

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Pharmacologic treatment of children and adolescents with inflammatory bowel diseases (IBD) [Crohn's disease and ulcerative colitis] requires consideration of disease and medication effects on growth and nutrition, the importance of durability of biologics, and concerns for long-term sequelae of disease and therapies. Achieving early remission in children with Crohn's disease correlates with improved outcomes and therefore allows a window of opportunity for maximizing growth. Thus, there is a great need to treat children and adolescents with the right drug at the right time while achieving adequate exposure. Improved understanding of disease phenotypes, disease natural history, and risk stratification will play a critical role in treatment selection for children, particularly as more therapeutic options become available. Here we summarize data supporting newer concepts of treating the individual child with IBD through targeted early biologic treatment, including utilization of therapeutic drug monitoring to optimize treatment effects and the use of early antitumor necrosis factor (TNF)-α therapies to mitigate long-term sequelae of the disease. Recent inception cohort studies provide important data regarding the risk stratification of children and adolescents with IBD, which support a move toward a personalized therapeutic approach to IBD in children and adolescents.

show abstract

Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohnʼs Disease

Abstract: ADA treatment resulted in growth rate normalization as early as week 26 in children with moderately to severely active Crohn's disease and growth impairment.

Cited by 25 publications

References 29 publications

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease

Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management

Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm

Contact Info

Product

Resources

About